Opdivo helps hold off cancer's return in melanoma

20 October 2022

Bristol Myers Squibb (NYSE: BMY) has presented data that reinforces the benefits of its immuno-oncology blockbuster Opdivo (nivolumab) in the earlier stages of melanoma.

The US pharma major announced results from the Phase III CheckMate -76K trial, in which Opdivo as an adjuvant therapy demonstrated a statistically-significant and clinically-meaningful benefit in recurrence-free survival (RFS) versus placebo in completely resected stage IIB or IIC melanoma.

"Growing body of evidence supporting the clinical benefit of Opdivo for the treatment of melanoma, from the metastatic setting to earlier stages of cancer"At a pre-specified interim analysis, the trial met its primary endpoint of RFS. Opdivo reduced the risk of recurrence or death by 58% versus placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK